Search for content, post, videos

Cobra Biologics receives the Queen’s Award for Enterprise in International Trade

Award

The international contract development and manufacturing organisation has been awarded the Queen’s Award 2018 for Enterprise, in the International Trade category.

Cobra has a 20 year track record of supporting the life science industry with contract development and manufacturing of biopharmaceuticals, from preclinical through to clinical trials and commercial supply and currently exports over 85% of its services from its facilities based in the UK and Sweden.

Cobra’s UK based GMP approved facility is a globally recognised centre of excellence for the development and production of biological material to support both gene- and immuno-therapy. In April 2017, Cobra announced a £15 million gene therapy expansion plan, to meet the increased demand from both plasmid DNA and viral vectors for Phase III and Commercial supply to support both existing and new customer requirements in the development of revolutionary disease therapies.

“I am immensely proud of what Cobra has achieved over the last few years, culminating in the Queen’s Award. International Trade is vitally important for Cobra and the work that we do is challenging and requires a committed work force whose skills and dedication attract business from all over the world. I would like also to thank the Office for Life Science, Innovate UK and the Department for International Trade for their support of our expansion plans in the UK,” said Peter Coleman, Chief Executive of Cobra Biologics.